# Justin R Hamilton

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 50 papers | 1,839 citations | 304743 22 h-index | 265206 42 g-index |
| 50 all docs | 50 docs citations | 50 times ranked | 2191 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 288-292. | 7.1 | 198 |
| 2 | Protection against thrombosis in mice lacking PAR3. Blood, 2002, 100, 3240-3244. | 1.4 | 178 |
| 3 | Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood, 2003, 102, 3224-3231. | 1.4 | 166 |
| 4 | Increased Expression of Protease-Activated Receptor-2 (PAR2) and PAR4 in Human Coronary Artery by Inflammatory Stimuli Unveils Endothelium-Dependent Relaxations to PAR2 and PAR4 Agonists. Circulation Research, 2001, 89, 92-98. | 4.5 | 138 |
| 5 | Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood, 2008, 112, 90-99. | 1.4 | 123 |
| 6 | Atypical Protease-Activated Receptor Mediates Endothelium-Dependent Relaxation of Human Coronary Arteries. Circulation Research, 1998, 82, 1306-1311. | 4.5 | 73 |
| 7 | The class II PI 3-kinase, PI3KC2Î±, links platelet internal membrane structure to shear-dependent adhesive function. Nature Communications, 2015, 6, 6535. | 12.8 | 67 |
| 8 | Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbÎ±. Redox Biology, 2015, 6, 640-647. | 9.0 | 59 |
| 9 | Protease-Activated Receptor (PAR) 1 but Not PAR2 or PAR4 Mediates Endothelium-Dependent Relaxation to Thrombin and Trypsin in Human Pulmonary Arteries. Journal of Cardiovascular Pharmacology, 2001, 38, 108-119. | 1.9 | 52 |
| 10 | Challenges and Opportunities in Protease-Activated Receptor Drug Development. Annual Review of Pharmacology and Toxicology, 2017, 57, 349-373. | 9.4 | 50 |
| 11 | Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery. British Journal of Pharmacology, 2000, 130, 181-188. | 5.4 | 46 |
| 12 | Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Reviews, 2015, 29, 179-189. | 5.7 | 43 |
| 13 | Inhibition of proteaseâ€activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. Journal of Thrombosis and Haemostasis, 2016, 14, 1642-1654. | 3.8 | 42 |
| 14 | Proteaseâ€activated receptor 4: from structure to function and back again. British Journal of Pharmacology, 2016, 173, 2952-2965. | 5.4 | 42 |
| 15 | Structure and function of the open canalicular system â€“ the plateletâ€™s specialized internal membrane network. Platelets, 2018, 29, 319-325. | 2.3 | 42 |
| 16 | Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood, 2004, 103, 152-154. | 1.4 | 40 |
| 17 | Essential role of platelet activation via protease activated receptor 4 in tissue factor-initiated inflammation. Arthritis Research and Therapy, 2008, 10, R42. | 3.5 | 35 |
| 18 | Differential Signaling by Protease-Activated Receptors: Implications for Therapeutic Targeting. International Journal of Molecular Sciences, 2014, 15, 6169-6183. | 4.1 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Protease-activated receptors as targets for antiplatelet therapy. Blood Reviews, 2009, 23, 61-65. | 5.7 | 33 |
| 20 | Discovery and antiplatelet activity of a selective PI3KÎ² inhibitor (MIPS-9922). European Journal of Medicinal Chemistry, 2016, 122, 339-351. | 5.5 | 31 |
| 21 | Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. , 2012, 134, 246-259. | | 28 |
| 22 | Class II Phosphoinositide 3-Kinases as Novel Drug Targets. Journal of Medicinal Chemistry, 2017, 60, 47-65. | 6.4 | 26 |
| 23 | A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. Blood Advances, 2018, 2, 1283-1293. | 5.2 | 24 |
| 24 | Enzymatic activation of endothelial protease-activated receptors is dependent on artery diameter in human and porcine isolated coronary arteries. British Journal of Pharmacology, 2002, 136, 492-501. | 5.4 | 21 |
| 25 | The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions. Thrombosis and Haemostasis, 2012, 107, 328-337. | 3.4 | 21 |
| 26 | Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?. International Journal of Molecular Sciences, 2019, 20, 5629. | 4.1 | 20 |
| 27 | Safety and efficacy of targeting platelet proteinaseâ€activated receptors in combination with existing antiâ€platelet drugs as antithrombotics in mice. British Journal of Pharmacology, 2012, 166, 2188-2197. | 5.4 | 18 |
| 28 | Inhibition of NMDA receptor function with an anti-GluN1-S2 antibody impairs human platelet function and thrombosis. Platelets, 2017, 28, 799-811. | 2.3 | 18 |
| 29 | Protease-activated receptor-2 turnover stimulated independently of receptor activation in porcine coronary endothelial cells. British Journal of Pharmacology, 1999, 127, 617-622. | 5.4 | 16 |
| 30 | Disrupting the platelet internal membrane via PI3KC2Î± inhibition impairs thrombosis independently of canonical platelet activation. Science Translational Medicine, 2020, 12, . | 12.4 | 16 |
| 31 | Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets. PLoS ONE, 2016, 11, e0165565. | 2.5 | 16 |
| 32 | Combined deficiency of PI3KC2Î± and PI3KC2Î² reveals a nonredundant role for PI3KC2Î± in regulating mouse platelet structure and thrombus stability. Platelets, 2016, 27, 402-409. | 2.3 | 15 |
| 33 | Shared roles for Scl and Lyl1 in murine platelet production and function. Blood, 2019, 134, 826-835. | 1.4 | 15 |
| 34 | The mode of anesthesia influences outcome in mouse models of arterial thrombosis. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 197-206. | 2.3 | 12 |
| 35 | The <scp>PI</scp> 3â€kinase <scp>PI</scp>3<scp>KC</scp>2Î± regulates mouse platelet membrane structure and function independently of membrane lipid composition. FEBS Letters, 2019, 593, 88-96. | 2.8 | 12 |
| 36 | Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 431-497. | 2.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs. Thrombosis and Haemostasis, 2013, 109, 164-167. | 3.4 | 10 |
| 38 | Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window. Annals of Translational Medicine, 2017, 5, 464-464. | 1.7 | 7 |
| 39 | An extensional strain sensing mechanosome drives adhesion-independent platelet activation at supraphysiological hemodynamic gradients. BMC Biology, 2022, 20, 73. | 3.8 | 7 |
| 40 | Ionotropic glutamate receptors in platelets: opposing effects and a unifying hypothesis. Platelets, 2021, 32, 998-1008. | 2.3 | 6 |
| 41 | Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention. International Journal of Molecular Sciences, 2022, 23, 4840. | 4.1 | 6 |
| 42 | Neutrophil cathepsin G proteolysis of protease-activated receptor 4Âgenerates a novel, functional tethered ligand. Blood Advances, 2022, 6, 2303-2308. | 5.2 | 5 |
| 43 | Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4â€"Mediated Thrombin Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 960-972. | 2.4 | 4 |
| 44 | Degranulation enhances release of a stable contractile factor from rabbit polymorphonuclear leukocytes. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1545-H1551. | 3.2 | 3 |
| 45 | Proteinase-activated receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, . | 0.2 | 3 |
| 46 | Perinatal lethality of <i>Par4</i><sup>â€"/â€"</sup> mice delivered by primiparous dams reveals spontaneous bleeding in mice without platelet thrombin receptor function. Platelets, 2018, 29, 196-198. | 2.3 | 2 |
| 47 | Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902. Platelets, 2020, 32, 1-4. | 2.3 | 2 |
| 48 | Analysis of the F2LR3 (PAR4) Single Nucleotide Polymorphism (rs773902) in an Indigenous Australian Population. Frontiers in Genetics, 2020, 11, 432. | 2.3 | 2 |
| 49 | The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population. Thrombosis and Haemostasis, 2022, 122, 1130-1138. | 3.4 | 1 |
| 50 | Proteinase-activated receptors in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, . | 0.2 | 0 |